Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Medicine (Baltimore) ; 102(46): e35841, 2023 Nov 17.
Artigo em Inglês | MEDLINE | ID: mdl-37986377

RESUMO

Evidence supporting a starting dose of 2 g/day of mycophenolate mofetil (MMF) in combination with tacrolimus (TAC) for renal transplantation (RT) is still limited, but maintaining a dose of <2 g could result in worse clinical outcomes in terms of acute rejection (AR). This study aimed to determine the association between AR and infectious and noninfectious complications after RT with a dose of 1.5 g vs 2 g of MMF. A prospective cohort study was performed with a 12-month follow-up of recipients of RT from living donors with low (1.5 g/day) or standard (2 g/day) doses of MMF. The association between adverse effects and complications and doses of MMF was examined using Cox proportional hazard models, and survival free of AR, infectious diseases, and noninfectious complications was evaluated using the Kaplan-Meier test. At the end of the follow-up, the incidence of infectious diseases was 52% versus 50% (P = .71) and AR was 5% versus 5% (P = .86), respectively. The survival rate free of gastrointestinal (GI) complications requiring medical attention was higher in the low-dose group than in the standard-dose dose (88% vs 45%, respectively; P < .001). The use of 1.5 g/day of MMF confers a reduction in GI complications without an increase in infectious diseases or the risk of AR.


Assuntos
Doenças Transmissíveis , Transplante de Rim , Humanos , Tacrolimo/efeitos adversos , Ácido Micofenólico/efeitos adversos , Imunossupressores/efeitos adversos , Transplante de Rim/efeitos adversos , México/epidemiologia , Estudos Prospectivos , Quimioterapia Combinada , Doenças Transmissíveis/etiologia , Hospitais , Rejeição de Enxerto/prevenção & controle , Rejeição de Enxerto/epidemiologia , Sobrevivência de Enxerto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA